UNITY-B A Prospective, Multicentric, Single-arm Study to Evaluate the Safety and Efficacy of the UNITY-B Biodegradable Balloon-Expandable Biliary Stent System in Subjects With Biliary Strictures
NCT ID: NCT04929821
Last Updated: 2023-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2017-10-16
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Percutaneous Biodegradable Biliary Stents for the Treatment of Benign Biliary Strictures.
NCT05556668
Kaffes Stent in the Management of Post-surgical Biliary Strictures
NCT03716232
Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction
NCT00280709
Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer
NCT02238613
Prospective Evaluation of Winged Biliary Stent Patency in Patients With Benign Biliary Obstruction
NCT03115411
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Use of a biodegradable stent would eliminate procedural risk and expense associated with stent removal. In addition, a stent made of highly biocompatible material may be less prone to induce hyperproliferative damage to the ductal system than would plastic or metal stents. For biliary applications, biodegradable stents have been evaluated in several in-vitro and animal studies that proved the stents for being safe and well tolerated. They provided an adequate radial force and resulted in complete stricture resolution within several months. The stents did not show any signs of biliary hyperplasia or integration in the epithelium. Moreover, they seem to have a self-clearing effect on attached biofilm as the outer layer sloughs during the degradation process similarly to the exfoliation of human skin. Also, the stent could be removed from the bile duct, thus offering the possibility of extraction if necessary, at various times after implant.
Therefore, the aim of this clinical study is to evaluate the safety and the efficacy of the UNITY-B Biodegradable Balloon Expandable Biliary Stent System for draining obstructed biliary ducts to improve bile flow in patients suffering under biliary strictures accompanied by jaundice and pruritus or to maintain good clinical status for patients already drained by PTBD or primary stenting.
STUDY DEVICE The UNITY Balloon-expandable Biodegradable Biliary Stent System is comprised of two main components: a balloon-expandable, biodegradable hybrid stent and an over-the-wire balloon catheter delivery system. The UNITY-B System provides a means of safely advancing the stent to the desired location within the common bile duct and, once in position, the stent is deployed by inflating the balloon. The balloon expands to the nominal diameter under nominal pressure. The process in which the UNITY- B stent degrades is through hydrolysis. Implantation is endoscopally guided (ERCP) and stent advancement and deployment by virtue of a guide wire and balloon catheter. In cases of altered anatomy this device can be used for percutaneous transhepatic access as well.
POPULATION Patients with biliary strictures and suffer under jaundice associated with tea color urine, pale stool and pruritus. Biliary drainage relieves both and improves related symptoms like anorexia, diarrhea, and disturbed sleep pattern and leads to improved quality of life. Patient with previous PTBD or stenting who need secondary stenting for prolonged good clinical status.
PRIMARY ENDPOINT (Safety) The primary safety endoint is the proportion of subjects experiencing biliary and procedural complications (post-ERCP pancreatitis, bleeding, perforation (bile/duodenum), misplacement, migration, bile occlusion, duct abrasion, duodenal abrasion, cholangitis, severe pain) and all-death within 30 days of the index procedure.
SECONDARY ENDPOINT (Efficacy) Clinical success; normal serum bilirubin level within 14 days after onset of drainage. Relief of jaundice and pruritus.
Technical success; completion of initial ERCP and stent deployment. Procedural success; rating of stent criteria. Each criteria will be evaluated and rated as 1 for exellent, 2 for good, 3 for fair and 4 for poor.A procedure will be considered as successful if the combined rate is \< 3.
Quality of life improvement by Self Assessment score at 1, 7, 14, 30, 90, 183, 274 and 365 days.
Biodegradation rate at 7, 14, 30, 90, 183, 274 and 365 days assesd by visual assessment at each follow-up visits when adequate examinations (X-ray, Endoscopy, MRI, CT, …) are performed.
Compiled Complication Rate at 7, 14, 90, 183, 274 and 365 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study Device Treated Group
Treated with the study device, UNITY-B Biodegradable Balloon-Expandable Biliary Stent System.
Biliary Duct Stenting
UNITY-B Balloon-expandable Biodegradable Biliary Stent deployment in obstructed biliary ducts.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biliary Duct Stenting
UNITY-B Balloon-expandable Biodegradable Biliary Stent deployment in obstructed biliary ducts.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Benign fibrotic distal bile duct obstruction
* Duct occlusion caused by cholelithiasis
* A benign fibrotic distal obstruction of the Common Bile Duct (CBD), demonstrated by presence of a stenosis on magnetic resonance cholangiopancreatography (MRCP) and/or ERCP with proximal ductal dilation and cholestatic liver enzymes levels
* Ductal anastomotic strictures
* Malignant Biliary stricture at least 1 cm distal to the hilum as well as periampullary hilar strictures not involving the papilla.
* Neoplasm diagnosed on clinical and imaging findings
* Post-ERCP pancreatitis
* Obstructive jaundice with evidence of pruritus, tea color urine and pale stool
* Abnormal Bilirubin rate or
* A planned exchange of plastic stents previously placed for management of symptomatic biliary stricture or
* A previous Percutaneous Transhepatic Biliary Drainage (PTBD) for management of symptomatic biliary stricture 2) Age ≥ 18 years old
Exclusion Criteria
1. Subject is unwilling to comply with the follow-up schedule
2. Life expectancy \< 12 m,
3. Inability to pass a guidewire through stricture
4. Contra-indication for endoscopy or interventional radiology
5. History of allergic reactions to one of the compounds of investigational product.
6. Subject is unable or refuses to give informed consent
7. Subject is pregnant or breastfeeding
8. Patient under tutorship
9. Currently participating in another trial before reaching first endpoint.
10. Pseudo Klatskin tumors (metastases in the liver hilum) and gallbladder carcinoma
11. Patient need additional biliary stenting with another device than the study device.
\-
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
QualiMed Innovative Medizinprodukte GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Queen Mary Hospital
Hong Kong, , Hong Kong
The Prince of Wales Hospital
Hong Kong, , Hong Kong
AIG Hospitals (Asian Institute of Gastroenterology)
Hyderabad, , India
Sunway Medical Centre
Kuala Lumpur, , Malaysia
Universityi Kebangsaan Malaysia (UKM)
Kuala Lumpur, , Malaysia
University Malaya Medical Centre (UMMC)Clinical Investigation Centre (CIC)
Kuala Lumpur, , Malaysia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QUA-CLI-UN-01/QM-IS-UTB-035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.